Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 30;9(3):e001621. doi: 10.1136/jitc-2020-001621

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Changes in intratumoral CD8⁺ T-cell density according to the primary analysis (biomarker evaluable analysis set; n=59). (A) Scatter graph showing intratumoral CD8⁺ T-cell density at baseline and week 6 in non-injected lesions. (B) Scatter graph showing week 6/week 1 ratio of intratumoral CD8⁺ T-cell density in non-injected lesions. Biomarker valuable analysis set for non-injected lesions includes all subjects in the safety analysis set who had the intratumoral CD8⁺ cell density recorded at baseline and week 6, and the week 6 measurements from the injected lesion.